One in five women had developed metabolic syndrome and just under half developed clinical obesity after almost four years of treatment with a combination of dolutegravir, tenofovir alafenamide and emtricitabine, final 192-week results of the ADVANCE study show.
In comparison, 12% of women taking dolutegravir/tenofovir disoproxil fumarate/emtricitabine in the study developed metabolic syndrome and 27% developed clinical obesity. Men developed metabolic syndrome and clinical obesity at lower rates on both regimens. The study investigators have previously estimated that the higher incidence of metabolic syndrome in people taking the tenofovir alafenamide-containing regimen would translate into four additional cases of diabetes per thousand people treated.
Read the full story at Aidsmap.
For more coverage of AIDS 2022 from Aidsmap, click here.
Source : Aidsmap
Related HIV and Co-Infections News
-
[Press release] ViiV Healthcare aims to close treatment gaps for children living with HIV with paediatric Dovato marketing applications to the EMA and FDA
-
Infectious Disease Advisor: Dolutegravir plus lamivudine maintains HIV-1 suppression without HBV reactivation
-
[CROI 2026] HIV i-Base: Nine comprehensive free reviews in Topics in Antiviral Medicine
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.